Journal article
Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
- Rordorf T Department of Oncology, University Hospital, Zürich, Switzerland. Electronic address: tamara.rordorf@usz.ch.
- Hassan AA Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
- Azim H Department of Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt.
- Alexandru E Institute of Oncology "Prof. Dr. Ion Chiricuta" (IOCN), Cluj-Napoca, Romania.
- Er O Acibadem University, Acibadem Maslak Hospital, Istanbul, Turkey.
- Gokmen E Ege University, Bornova-Izmir, Turkey.
- Güral Z I.T.F. Radyasyon Onkolojisi Anabilim Dalı, Istanbul, Turkey.
- Mardiak J National Cancer Center, Bratislava, Slovakia.
- Minchev V University Multiprofile Hospital for Active Treatment and Emergency Medicine, Plovdiv, Bulgaria.
- Peintinger F General Hospital, Leoben-Eisenerz, Austria.
- Szendroi M SE Ortopédiai Klinika, Budapest, Hungary.
- Takac I Maribor Teaching Hospital, Maribor, Slovenia.
- Tesarova P Onkologická klinika, Praha, Czech Republic.
- Vorobiof D Sandton Oncology Centre, Johannesburg, South Africa.
- Vrbanec D Oncology Clinic, Zagreb, Croatia.
- Yildiz R Gazi University Faculty of Medicine, Ankara, Turkey.
- Yücel S Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
- Zekri J Jeddah King Faisal Specialist Hospital & Research Centre, Khaldia, Saudi Arabia.
- Oyan B Yeditepe University Hospital, Istanbul, Turkey.
- 2014-07-03
Published in:
- Breast (Edinburgh, Scotland). - 2014
Bisphosphonates
Bone metastases
Denosumab
Metastatic breast cancer
Radiotherapy
Skeletal-related events
Bone Density Conservation Agents
Bone Neoplasms
Breast Neoplasms
Combined Modality Therapy
Female
Humans
Treatment Outcome
English
Bone is the most common site of distant metastases in breast cancer that can cause severe and debilitating skeletal related events (SRE) including hypercalcemia of malignancy, pathologic fracture, spinal cord compression and the need for palliative radiation therapy or surgery to the bone. SRE are associated with substantial pain and morbidity leading to frequent hospitalization, impaired quality of life and poor prognosis. The past 25 years of research on the pathophysiology of bone metastases led to the development of highly effective treatment options to delay or prevent osseous metastases and SRE. Management of bone metastases has become an integral part of cancer treatment requiring expertise of multidisciplinary teams of medical and radiation oncologists, surgeons and radiologists in order to find an optimal treatment for each individual patient. A group of international breast cancer experts attended a Skeletal Care Academy Meeting in November 2012 in Istanbul and discussed current preventive measures and treatment options of SRE, which are summarized in this evidence-based consensus for qualified decision- making in clinical practice.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1016/j.breast.2014.05.023
- PMID 24986766
- Persistent URL
- https://sonar.ch/global/documents/263391
Statistics
Document views: 32
File downloads: